首页> 美国卫生研究院文献>PLoS Clinical Trials >Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

【2h】

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

机译：接受辅助性他莫昔芬单药治疗的高危ER +乳腺癌患者的全球MicroRNA表达谱：一项DBCG研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeDespite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to probability of recurrence.

机译：目的尽管针对雌激素受体（ER）的内分泌疗法在乳腺癌中具有优势，但许多肿瘤仍会产生耐药性。 MicroRNA（miRNA）被认为是有前途的生物标志物，我们在这里评估了是否可以鉴定出miRNA概况，将三苯氧胺+辅助用他莫昔芬治疗的ER +乳腺癌患者分为复发几率。

著录项

期刊名称 PLoS Clinical Trials
作者
Maria B. Lyng; Anne-Vibeke Lænkholm; Rolf Søkilde; Karina H. Gravgaard; Thomas Litman; Henrik J. Ditzel;
展开▼
作者单位

展开▼
年(卷),期 2009(7),5
年度 2009
页码 e36170
总页数 7
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The course and prognosis for loco-regional recurrences among high-risk breast cancer patients receiving adjuvant systemic treatment and randomized to +/? postmastectomy radiotherapy. Long-term results from the Danish DBCG 82b&c studies with 3083 patients [J] . H.M.Nielsen, M.Overgaard, C.Grau, European Journal of Cancer Supplements . 2004,第3期

机译：接受辅助全身治疗并随机分为+ /？的高危乳腺癌患者局部区域复发的过程和预后乳房切除术后放疗。丹麦DBCG 82b＆c研究对3083名患者的长期结果
2. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial [J] . KnoopA.S., L?nkholmA.-V., JensenM.-B., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第8期

机译：参与DBCG 77C试验的绝经后高危乳腺癌患者的雌激素受体，孕激素受体，HER2状态和Ki67指数以及对他莫昔芬的辅助治疗反应
3. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies [J] . Nielsen HM, Overgaard M, Grau C, Journal of Clinical Oncology . 2006,第15期

机译：除辅助全身治疗外，在有或没有乳房切除术后放疗的高危乳腺癌患者中的失败模式研究：丹麦乳腺癌合作组织DBCG 82b和c的随机研究的长期结果
4. Analyzing mRNA and microRNA co-expression profiles to identify pathways and their potential regulators in ER+ and ER- breast tumors [C] . Huang Lei, Roqueiro Damian, Dai Yang 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2011

机译：分析mRNA和microRNA的共表达谱，以鉴定ER +和ER-乳腺肿瘤的途径及其潜在调控因子
5. Translational Reprogramming by eIF4E in Tamoxifen-Resistant ER+ Breast Cancer. [D] . Geter, Phillip A. 2018

机译：eIF4E在抗他莫昔芬的ER +乳腺癌中进行翻译重编程。
6. Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study [O] . Maria B. Lyng, Anne-Vibeke Lænkholm, Qihua Tan, 2010

机译：预测他莫昔芬治疗的雌激素受体阳性，高危原发性乳腺癌患者结果的基因表达特征：一项DBCG研究
7. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy:a DBCG study [O] . Lyng, Maria Bibi, Lænkholm, Anne-Vibeke, Søkilde, Rolf, 2012

机译：接受他莫昔芬辅助疗法单药治疗的高危ER +乳腺癌的整体microRNA表达谱：一项DBCG研究
8. Randomized Trial of Neuroprotective Effects of Erythropoietin in Patients Receiving Adjuvant Chemotherapy for Breast Cancer: Positron Emission Tomography and Neuropsychological Study [R] . Abraham, J. 2008

机译：促红细胞生成素对接受乳腺癌辅助化疗的患者的神经保护作用的随机试验：正电子发射断层扫描和神经心理学研究

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

摘要

著录项

相似文献

相关主题

期刊订阅